Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19-CAR T cells + CD20-CAR T cells
- Development stage
- Unknown
- Lead developer
- Guizhou Medical University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD19-CAR T cells + CD20-CAR T cells is a dual-targeted chimeric antigen receptor T-cell therapy that targets both CD19 and CD20 antigens on B cells. This combination approach is designed to address antigen escape and loss of T-cell functionality in B-cell malignancies. The therapy involves engineering a patient's own T cells to express chimeric antigen receptors that recognize both CD19 and CD20 antigens, enabling the modified T cells to target and kill cancer cells expressing either or both antigens. Clinical trials have shown promising efficacy and safety profiles in patients with relapsed/refractory non-Hodgkin lymphoma and central nervous system lymphomas.
- Brand names
- Prizloncabtagene autoleucel
- Other names
- CART19/20CD19/CD20 bispecific CAR T-cell therapyCD19/CD20 CAR
02
Targets
Beyond the preview
Go deeper on CD19-CAR T cells + CD20-CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19-CAR T cells + CD20-CAR T cells.